Clinical Trial Update: Ranolazine, Ethnicity and the Metabolic Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating ranolazine across ethnic groups in patients with coronary artery disease and angina, including metabolic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease
• Metabolic Syndrome

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Sponsor: Atlanta Heart Specialists, LLC | Conditions: Coronary Artery Disease, Angina | Phase 4 | Status: UNKNOWN